Clinical Trials Browser

Recurrence × perflutren × 90 days × Clear all

NCT07501650 2026-03-30

Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer

Phase 1 Recruiting

Head and Neck Neoplasms, Recurrence